[Asia Economy Reporter Lee Jung-yoon] UbioLogics announced on the 2nd that it has been selected as the lead institution for the 2nd new project of 2022 under the Ministry of Health and Welfare's National New Drug Development Foundation COVID-19 Therapeutics and Vaccine New Drug Development Project and has signed an agreement.
The project is titled "Phase 3 Clinical Trial and Export Product Approval of Ucovac-19," with a total research period from last month 1st to June 30, 2023. The total project budget amounts to 24.8793 billion KRW.
The company explained, "Ucovac-19 is a SARS-CoV-2 recombinant protein vaccine that incorporates a liposome-formulated immune adjuvant, which is expected to provide sufficient COVID-19 prevention effects with a small amount of antigen," adding, "We aim to develop a COVID-19 vaccine that can be stored refrigerated and has price competitiveness."
They continued, "We expect active entry into low- and middle-income countries by developing a COVID-19 vaccine with distribution convenience and price competitiveness," and added, "The development of the COVID-19 vaccine is expected to secure vaccine sovereignty and enable rapid response in the event of another pandemic in the future."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
